# TENAYA and LUCERNE

*PRI Rank #7 · Topics and Trends in Most Cited Retinal Diseases and Treatments Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/retinal-diseases-and-treatments/2026/rank-7*

| Field | Value |
| --- | --- |
| Rank | #7 |
| 18m citations | 71 |
| Journal | Ophthalmology |
| Year | 2024 |
| DOI | 10.1016/j.ophtha.2024.02.014 |
| Corresponding authors | Arshad M. Khanani |
| Institution | University of Nevada, Reno, United States |

**Ranking page:** [Topics and Trends in Most Cited Retinal Diseases and Treatments Papers, Class of 2026](https://pri.pepkio.com/top-papers/retinal-diseases-and-treatments/2026)

**Paper link:** [10.1016/j.ophtha.2024.02.014](https://doi.org/10.1016/j.ophtha.2024.02.014)

## Topics

Faricimab · Faricimab · Angiopoietin-2 inhibition · Anti-VEGF therapy · Neovascular age-related macular degeneration · Aflibercept · Intravitreal injection · Treat-and-extend regimen · Every-16-week dosing · Q12W dosing · Q8W dosing · Best-corrected visual acuity (BCVA) · Noninferiority trial design · Treatment-naïve · Extended dosing interval · ocular adverse events · TENAYA trial · LUCERNE trial · disease activity-based dosing · Durability of treatment effect

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Retinal Diseases and Treatments Papers, Class of 2026. https://pri.pepkio.com/top-papers/retinal-diseases-and-treatments/2026. Accessed 2026-07-14.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```